17 results about "Immunoglobulin M" patented technology

A lyophilized composition comprising a polyclonal immunoglobulin M (IgM) comprising the steps of: a) providing an initial aqueous solution comprising IgM at a concentration of from about 10 mg / mL to about 50 mg / mL, the polyclonal IgM being at least about 90% by weight of the total protein content in the composition; b) adding an amino acid selected from the group consisting of proline, glycine, alanine, valine and hydroxyproline, or mixtures thereof, at a final concentration of from about 0.15 M to about 0.45 M, polysorbate 80 (PS80) at a concentration of from about 50 to about 200 ppm, and succinic acid at a concentration of from about 1 mM to about 20 mM; and c) lyophilizing the IgM composition obtained in the step b), wherein the content of pentamer IgM in the lyophilized composition is greater than about 90% of the total IgM content, and the content of IgM aggregate is less than about 1.5%.

The invention discloses a detection test strip and a detection card for detecting a coxsackie virus group B IgM antibody as well as a preparation method and application of the detection test strip and the detection card. The detection test strip comprises a bottom plate as well as a nitrocellulose membrane, absorbent paper, a conjugate pad and a sample pad which are sequentially overlapped and fixed on the bottom plate, the nitrocellulose membrane is coated with a detection line and a quality control line, the detection line is coated with an antigen of an anti-coxsackie virus group B IgM antibody, and the quality control line is coated with an IgG polyclonal antibody; the conjugate pad comprises an antigen conjugate of a colloidal gold-anti-coxsackie virus group B IgM (Immunoglobulin M) antibody; the particle size of the colloidal gold is larger than or equal to 100 nm. The detection test strip prepared by the invention is high in sensitivity, good in repeatability and strong in specificity, and can be used for detecting the coxsackie virus group B IgM antibody. The device is convenient to use, easy to operate, short in consumed time and convenient to carry.

A molecular marker associated with immune parameters in yaks and use thereof in breeding are provided. A single nucleotide polymorphism (SNP) molecular marker associated with immune traits in yaks is identified through screening. The SNP molecular marker is located at position 26593056 on chromosome 3 of the yak reference genome version LU_Bosgru_v3.0, and a nucleotide at the position is G or A. The SNP molecular marker is utilized to quantify levels of immunoglobulin A, immunoglobulin G, and immunoglobulin M in a yak individual, providing a novel SNP molecular marker resource for non-diagnostic, marker-assisted selection of immune traits in yaks, thereby providing a basis for breeding yaks with enhanced immune competence.

Provided is an adapter comprising an antibody binding domain (AbBD) that specifically binds and crosslinks to an immunoglobulin Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, G32, Q35, S36, N46, G49, E50, K53 or L54 of SEQ ID NO: 1 or combinations thereof, and where the AbBD is photoreactive. Also provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region and / or to an immunoglobulin M (IgM) Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement / modification at A28, E50, or L54 of SEQ ID NO: 1 or combinations thereof, where the AbBD is photoreactive. Provided is an adapter comprising an AbBD that specifically binds and crosslinks to an IgG Fab region, where the AbBD is a variant of a Protein L C* domain and has an amino acid replacement / modification at G22 or T46 of SEQ ID NO: 2 or a combination thereof, wherein the AbBD is photo-reactive. Methods for using the AbBD for imaging, diagnosing and / or treating a disease are provided.

The invention provides a method for removing IgA (Immunoglobulin A) and IgM (Immunoglobulin M) in human immunoglobulin for intravenous injection. The method comprises the following steps: S1) dissolving plasma component II + III precipitates to obtain a dissolved solution; s2) precipitating and centrifuging the dissolved solution by adopting n-caprylic acid or sodium caprylate to obtain supernate; s3) performing anion exchange column chromatography on the supernate to obtain first flow-through liquid and first washing liquid; s4) mixing the first flow-through liquid with the first washing liquid to obtain a column chromatography collection liquid; s5) performing strong anion membrane chromatography on the column chromatography collection liquid to obtain second flow-through liquid and second washing liquid; s6) mixing the second flow-through liquid and the second washing liquid to obtain a membrane chromatography collection liquid, and S7) sequentially performing first concentration, dialysis, first sterilization, incubation, ultrafiltration and second sterilization on the membrane chromatography collection liquid to obtain the human immunoglobulin for intravenous injection without IgA and IgM. According to the method disclosed by the invention, the IgA and IgM removal efficiency is remarkably improved through a multi-stage purification process.

This invention provides an immunological assay method capable of suppressing nonspecific reactions caused by immunoglobulin M, abbreviated as IgM, contained in a sample for measurement, and reagents used in this immunological assay method. [Solution] The present invention provides an immunological assay method for measuring a target substance in a sample, comprising performing an antigen-antibody reaction at least once in the presence of an enzyme that specifically degrades IgM, and an immunological assay reagent used in the immunological assay method, comprising an enzyme that specifically degrades IgM.

A method of preventing or treating or controlling a respiratory disease in a bovine by delivering to a lung or trachea of the bovine a composition including a polyplex having one or more mRNA encoded with a molecule selected from lycosylphosphatidylinositol (GPI) complex, antibody immunoglobulin G (IgG), antibody immunoglobulin A (IgA), antibody immunoglobulin M (IgM), antimicrobial peptide Bactenecin 5 (Bac5), antimicrobial peptide Bactenecin 7 (Bac7), bovine myeloid antimicrobial peptide (BMAP-28), lipoxin inducing enzymes, resolvin inducing enzymes, cytokines, CRISPR associated protein 13 (Cas13) enzymes, nanoluciferase (NLuc) proteins, and gene activator, catalytically dead CRISPR-associated protein 9 fused to an activator selected from the group consisting of VP64-p65-Rta transactivation domain (dCas9-VPR), VP64, and VP64-p65-HSF1 on the N terminus and SS18 on the C-terminus, and a polymer prepared by polymerizing a diacrylate monomer; one or more linker monomers; and one or more branching monomers; and end-capping the polymer.

An immunological measurement method for measuring a measurement target substance in a sample, wherein an antigen-antibody reaction is conducted at least once or more in the presence of an enzyme that specifically degrades Immunoglobulin M, abbreviated as IgM.

The invention belongs to the technical field of genetic engineering, and particularly relates to preparation and application of a PRRSV (porcine reproductive and respiratory syndrome virus) specific mouse-pig chimeric IgM antibody. The invention provides two PRRSV (porcine reproductive and respiratory syndrome virus) mouse-pig chimeric IgM (immunoglobulin M) antibodies expressed by genetic engineering recombination, the antibodies comprise a mouse-pig chimeric antibody M1-sIgM and a mouse-pig chimeric antibody M2-sIgM, and the mouse-pig chimeric antibody M1-sIgM has a light chain sequence as shown in SEQ ID NO: 1 and a heavy chain sequence as shown in SEQ ID NO: 2; the mouse and pig chimeric antibody M2-sIgM has a light chain sequence as shown in SEQ ID NO: 5 and a heavy chain sequence as shown in SEQ ID NO: 6. The two antibodies provided by the invention can be used independently or jointly as immunopotentiators of the PRRSV inactivated vaccine to enhance the protective effect of the PRRSV inactivated vaccine.

The present invention relates to an immunological measurement method for measuring a substance to be measured in a sample, the method comprising performing at least one antigen-antibody reaction in the presence of an enzyme that specifically decomposes an immunoglobulin M abbreviated as IgM.

FIELD: occupational medicine.SUBSTANCE: used to diagnose immunocompromise in workers exposed to mixed aerosols containing crystalline silicon dioxide from 10 to 70% and metals in the solid phase. Samples of venous blood and smears from the mucous membrane of the pharynx are taken. In the presence of Streptococcus pneumoniae DNA in scrapings from the mucous membrane of the pharynx and with the level of immunoglobulin M in the blood serum≤ 1.7 g / l is used to diagnose immunocompromise in workers exposed to mixed aerosols containing crystalline silicon dioxide from 10 to 70% and metals in the solid phase.EFFECT: method provides the possibility of selecting immunocompromised workers exposed to industrial mixed aerosols for priority vaccination against pneumococcal infection at the stage of periodic medical examination, by determining the level of immunoglobulin M in the blood serum and Streptococcus pneumoniae DNA in swabs from the mucous membrane of the pharynx.1 cl, 1 tbl, 1 ex

The present application relates to methods of treating infectious diseases with compositions containing plasma-derived immunoglobulin M (IgM). The compositions and methods of the invention prevent, inhibit, or reduce the toxic effects of proteins and toxins secreted by microorganisms. A method for neutralizing a microbial protein product in a subject includes administering to the subject a composition comprising plasma-derived IgM and, optionally, one or more excipients in the form of a pharmaceutical carrier, wherein the composition is administered in an amount effective to neutralize the microbial protein product.

The present invention belongs to the technical field of molecular biological detection, and particularly relates to a molecular marker associated with a yak immune index and the use thereof in breeding. In the present invention, an SNP molecular marker associated with a yak immune trait is obtained by means of screening. The marker is located at base position 26593056 on chromosome 3 of the yak reference genome assembly LU_Bosgru_v3.0, with the mutant base being G or A. In the present invention, the contents of immunoglobulin A, immunoglobulin G and immunoglobulin M in a yak individual can be obtained by using the SNP molecular marker, which provides a new SNP molecular marker resource for marker-assisted selection of yak immune traits for non-diagnostic purposes, thereby providing a basis for the breeding of yaks with high immunity.

The present application relates to the technical field of molecular biology detection, and provides a SNP molecular marker affecting yak immunoglobulin and application of the SNP molecular marker. The present application obtains, through screening, that the SNP molecular marker related to the yak immunity trait is located at the 43165308th base on the 21st chromosome of the yak reference genome LU_Bosgru_v3.0, and the mutation base is C or T. The molecular marker can determine the contents of immunoglobulin A and immunoglobulin M of a yak individual. The present application provides a new SNP molecular marker resource for marker-assisted selection of non-diagnostic yak immunity traits, and provides a basis for improving the breeding of yak immunity.

The invention belongs to the technical field of biology, particularly relates to an anti-swine IgM (immunoglobulin M) murine monoclonal antibody and application, and particularly provides a sequence of the monoclonal antibody, the monoclonal antibody has the advantages of good purity, good specificity, no cross reaction with swine IgA and IgG, high reactivity, only specific binding with a heavy chain of swine IgM, titer of greater than 1: 32,000, and IgG1 type heavy chain and kappa type light chain, a reliable research tool is provided for early differential diagnosis of porcine epidemic diseases; when the monoclonal antibody is applied to ASFV detection, a result shows that the window period of an ASFV IgM ELISA antibody detection method is shorter, the detected ASFV antibody is obviously earlier than that of a commercial kit, and the ASFV monoclonal antibody has a wide application prospect.

The utility model discloses a portable fish Igm (Immunoglobulin m) monoclonal antibody colloidal gold test paper box which comprises a detection component, a detection component and a detection component, the drawing assembly comprises a mounting groove, a drawer, a foam block, a mounting hole, a first connecting belt, a first hook-and-loop fastener, a second hook-and-loop fastener and a fixing piece, the mounting groove is formed in the lower end of one face of the test paper box, the drawer is slidably mounted in the mounting groove, the foam block is placed in the drawer, and the mounting hole is formed in the top face of the foam block; the first connecting band is adhered to the lower side of one surface of the drawer, the first magic tape is fixedly connected to the lower end of the first connecting band, and the second magic tape is fixedly connected to the upper end of the first connecting band. The test paper box has the advantages that the drawer type design allows more reasonable utilization of the internal space of the test paper box, the storage positions and the number of the test tubes can be adjusted as required, and the test tubes are safely limited in the test paper box before and after sampling, so that the pollution of the external environment to samples can be reduced.

The invention discloses an IgM (Immunoglobulin M)-imitated multivalent nucleic acid aptamer-albumin nano-carrier, and belongs to the technical field of anti-tumor drug delivery. The nano-carrier is formed by self-assembly of an IgM-like nucleic acid aptamer (TYA) and albumin (HSA) through hydrophobic interaction; the TYA is prepared by carrying out amidation reaction on poly (maleic anhydride-alt-1-octadecene) (C18PMH), Boc-PEG-NH2 and a COOH <-> modified nucleic acid aptamer through covalent coupling on the poly (maleic anhydride-alt-1-octadecene) (C18PMH) and the Boc-PEG-NH2. According to the present invention, the IgM-imitated series Y-shaped structure design is adopted, such that the problems of poor stability and insufficient targeting binding force of the existing aptamer modified albumin carrier are solved, the occupation of the albumin hydrophobic cavity is reduced, the drug loading rate is increased to 1.686%, and the in-vivo retention time is prolonged to 8 h. The nano-carrier has excellent tumor targeting property and anti-tumor effect, and a novel efficient carrier is provided for targeted delivery of anti-tumor drugs.